Search research articles
Contact Us
Filters
Showing results (91-100 of 115) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 15, 2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure
Nizar M Tannir, Yu-Ning Wong, Christian K Kollmannsberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2023
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
Lancet (London, England)
|
November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I Rini, Bernard Escudier, Piotr Tomczak, et al.
European Urology Oncology
|
July 13, 2023
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
Douglas M Dahl, Theodore G Karrison, M Dror Michaelson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)
Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
David J Kwiatkowski, Toni K Choueiri, André P Fay, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 27, 2009
NCCN clinical practice guidelines in oncology: testicular cancer
Robert J Motzer, Neeraj Agarwal, Clair Beard, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 27, 2009
NCCN clinical practice guidelines in oncology: kidney cancer
Robert J Motzer, Neeraj Agarwal, Clair Beard, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 115) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 15, 2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure
Nizar M Tannir, Yu-Ning Wong, Christian K Kollmannsberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2023
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
Lancet (London, England)
|
November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I Rini, Bernard Escudier, Piotr Tomczak, et al.
European Urology Oncology
|
July 13, 2023
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
Douglas M Dahl, Theodore G Karrison, M Dror Michaelson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)
Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
David J Kwiatkowski, Toni K Choueiri, André P Fay, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 27, 2009
NCCN clinical practice guidelines in oncology: testicular cancer
Robert J Motzer, Neeraj Agarwal, Clair Beard, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 27, 2009
NCCN clinical practice guidelines in oncology: kidney cancer
Robert J Motzer, Neeraj Agarwal, Clair Beard, et al.
Page
of 12